See more : Xvivo Perfusion AB (publ) (XVIPF) Income Statement Analysis – Financial Results
Complete financial analysis of Cellid, Co., Ltd. (299660.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellid, Co., Ltd., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Array Technologies, Inc. (ARRY) Income Statement Analysis – Financial Results
- Alphabet Inc. (ABEC.DE) Income Statement Analysis – Financial Results
- Tabikobo Co. Ltd. (6548.T) Income Statement Analysis – Financial Results
- M-tron Industries, Inc. (MPTI) Income Statement Analysis – Financial Results
- The People’s Insurance Company (Group) of China Limited (601319.SS) Income Statement Analysis – Financial Results
Cellid, Co., Ltd. (299660.KQ)
About Cellid, Co., Ltd.
Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 480.00M | 909.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 639.82M |
| Cost of Revenue | 4.86M | 2.86B | 2.29B | 492.00M | 109.51M | 76.54M | 69.81M | 64.85M | 0.00 |
| Gross Profit | -2.66B | -2.38B | -1.38B | -492.00M | -109.51M | -76.54M | -69.81M | -64.85M | 639.82M |
| Gross Profit Ratio | 0.00% | -495.54% | -151.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 7.47B | 7.89B | 15.76B | 3.02B | 3.13B | 3.36B | 1.94B | 1.51B | 1.13B |
| General & Administrative | 629.60M | 638.40M | 762.12M | 169.42M | 12.77M | 2.57M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 927.15M | 852.23M | 988.64M | 528.94M | 268.97M | 255.74M | 0.00 | 0.00 | 0.00 |
| SG&A | 4.79B | 4.40B | 4.39B | 1.61B | 1.38B | 609.24M | 325.42M | 212.15M | 692.98M |
| Other Expenses | 2.80M | -249.21M | -165.44M | -171.13M | -61.24M | -946.62K | -15.27M | -607.96K | 0.00 |
| Operating Expenses | 12.20B | 12.53B | 20.31B | 4.79B | 4.57B | 3.97B | 2.28B | 1.72B | 1.82B |
| Cost & Expenses | 12.20B | 15.39B | 22.60B | 5.29B | 4.68B | 4.05B | 2.35B | 1.79B | 1.82B |
| Interest Income | 631.03M | 955.91M | 919.20M | 1.11B | 930.29M | 186.29M | 64.33M | 56.75M | 28.39M |
| Interest Expense | 1.26B | 1.63B | 536.29M | 12.55M | 5.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.66B | 2.60B | 2.29B | 492.00M | 109.51M | 76.54M | 69.81M | 64.85M | 0.00 |
| EBITDA | -7.68B | -18.64B | -10.25B | -3.62B | -2.38B | -11.21B | -5.34B | -1.71B | -1.18B |
| EBITDA Ratio | 0.00% | -2,564.85% | -2,134.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -184.26% |
| Operating Income | -12.20B | -14.91B | -21.69B | -5.29B | -4.68B | -4.05B | -2.35B | -1.79B | -1.18B |
| Operating Income Ratio | 0.00% | -3,106.53% | -2,385.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -184.26% |
| Total Other Income/Expenses | 586.52M | -7.95B | -59.64M | 1.16B | 1.04B | -7.24B | -3.06B | 17.24M | 53.93M |
| Income Before Tax | -11.61B | -22.86B | -13.07B | -4.13B | -2.49B | -11.29B | -5.41B | -1.77B | -1.13B |
| Income Before Tax Ratio | 0.00% | -4,763.45% | -1,437.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -175.83% |
| Income Tax Expense | 3.00 | 5.00 | 1.00 | -4.00 | 1.00 | 76.38M | -2.00 | 4.00 | 0.00 |
| Net Income | -11.61B | -22.86B | -13.07B | -4.13B | -2.49B | -11.29B | -5.41B | -1.77B | -1.13B |
| Net Income Ratio | 0.00% | -4,763.45% | -1,437.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -175.83% |
| EPS | -1.08K | -2.14K | -1.23K | -389.92 | -242.12 | -979.71 | -469.47 | -153.78 | -108.59 |
| EPS Diluted | -1.08K | -2.14K | -1.23K | -389.92 | -242.12 | -979.71 | -469.47 | -153.78 | -108.59 |
| Weighted Avg Shares Out | 10.77M | 10.68M | 10.66M | 10.58M | 10.30M | 11.52M | 11.52M | 11.52M | 10.36M |
| Weighted Avg Shares Out (Dil) | 10.77M | 10.68M | 10.66M | 10.58M | 10.30M | 11.52M | 11.52M | 11.52M | 10.36M |
Source: https://incomestatements.info
Category: Stock Reports